The FDA has expanded the approval of Repatha to reduce the risk of major adverse cardiovascular events in adults at increased risk for these events.

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

A renowned senior cardiologist in our area has been taking all his patients off statins and putting them on Repatha. He did this for my husband, and the results have been amazing. Within three months, ...

Kerstin Wolff and Tobias Matschke of Maiwald Intellectual Property examine a landmark Unified Patent Court decision on second medical use claims and compare it with Germany’s established approach to ...

It can reveal plaque in arteries, offering a more precise estimate of a person’s risk of heart disease. Yet the test remains ...

Q. My doctor prescribed a Cologuard instead of a colonoscopy. No one mentioned how often Cologuard could result in false positive test results as mine did. So, a colonoscopy was necessary after all, ...

Amgen, a biotechnology company that discovers, develops, manufactures and delivers innovative medicines, announced that the US Food and Drug Administration (FDA) has broadened the approved use of ...

Amgen recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...